To evaluate the in vivo antitumor efficacy of CD19-BBζ + CD2 cells, we initially established an acute leukemia model by engrafting 5 × 105 Nalm6 tumor cells overexpressing luciferase (Nalm6-L) one week prior to CAR-T-cell therapy. The gene discussed is CD19; the disease is neoplasm.